Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: December 7, 2022

Details for Patent: 8,758,733

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,758,733 protect, and when does it expire?

Patent 8,758,733 protects LATISSE and is included in one NDA.

This patent has seventeen patent family members in eight countries.

Summary for Patent: 8,758,733
Title:Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s): Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney G. (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/738,732
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,758,733

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF INCREASING EYELASH GROWTH See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,758,733

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003207843 See Plans and Pricing
Australia 2008203212 See Plans and Pricing
Australia 2010227111 See Plans and Pricing
Australia 2012261499 See Plans and Pricing
Australia 2013208002 See Plans and Pricing
Canada 2475106 See Plans and Pricing
European Patent Office 1471876 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.